Shots:

• The P- III KESTREL trial involves assessing of Imfinzi (durvalumab) or Imfinzi + tremelimumab vs EXTREME treatment regimen (CT+ cetuximab) in patients as a 1L treatment for patients with recurrent or m-HNSCC whose tumors expressed high levels of PD-L1
• The trial failed to meet its 1EPs of improving OS while the combination did not indicate an OS benefit in all-comer patients as 2EPs. The safety & tolerability for Imfinzi as a monothx. and in combination were consistent with previous trials
• Imfinzi is a human mAb that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80- countering the tumor's immune-evading tactics and releasing the inhibition of immune responses

 ­ Ref: AstraZeneca | Image: New Europe